inLife are now aiming their new PIF Starter Kits featuring the market leader regal 2 e-cig directly at the retail market by offering 10 kits to distributors at a $99 price.

There is no cost to become an inLife distributor when you purchase a minimum of 10 kits. inLife also offers a free website to retailers for customers to reorder cartridges plus a state of the art customer service division to handle enquiries and support.

In fact with the counter top displays and leaflets that accompany the campaign, the retail outlet need do little more than display prominently to start to earn a residual income from repeat cartridge sales from its purchasing customers.

Regal 2 cartridges come in boxes of 8 cartridges.

We discount so you can buy in bulk and save even more money..

4 Boxes …….  $95.97 ( Save $25)

10 Boxes…..   $224.63 (Save $75)

20 Boxes…..   $419.30 (Save $180)

50 Boxes…..   $973.38 (Save over $500)

Note: For 10, 20 & 50 Box purchases you need to select Regal 2 Multi-pack  in shop (the 10 box packs are at the end). For single and 4 box just select Regal 2 Cartridges)

This means that for a pack a day tobacco smoker, you should be able to get a months supply for under $100…..a great saving on todays cost of tobacco!

Retailers can get the unit price of a box under $20 a box giving a great margin on local sales.

Retailers wishing to stock the PIF Regal 2 starter kits in the USA, or Europe should e-mail neil@myinlife.co.uk with their company details.

Wholesale accounts for retailers are free and need only purchase a 10 PIF pack ($99) plus counter display ($13.50) to be able to start selling Regal2 e-cigs.

A retail website and full customer service is provided so retailers can earn residual income from cartridge re-orders.

The Spanish Department of Health is proposing that the cost of cigarettes and other tobacco products be doubled.This would bring the cost into line with many other European countries such as the UK and France.At the moment Spain is the cheapest place in Europe to purchase cigarettes.

Tobacco is a very dangerous material and people smoke it for the effect of nicotine.It is the chemicals in the tobacco which cause all of the health problems such as cancer and respiratory and circulatory diseases.Nicotine which is not derived from tobacco is not a major health hazard and can be smoked via an electronic cigarette.

Consequently electronic cigarettes can give the smoker the feeling that they want and will not affect their health in the same way.There is no smoke,only water vapour, no smell, no ash, no fire risk ,in fact they are the perfect alternative for smokers.It is important that people purchase nicotine which is synthetic and pure and Inlife electronic cigarettes do just that.( www.myinlife.eu)

The Spanish government is going down the right path and should be promoting the use of these smoking alternatives instead.

Original Post: AMLA Spanish News

Coriolus PSP (Polysaccharide Peptide), used in Asia for its medicinal benefits has been found to be 100 per cent effective in suppressing prostate tumour development in mice during early trials, new Queensland University of Technology (QUT) research shows.

The compound, polysaccharopeptide (PSP), which is extracted from the ‘turkey tail’ mushroom, was found to target prostate cancer stem cells and suppress tumour formation in mice, an article written by senior research fellow Dr Patrick Ling in the international scientific journal PLoS ONE said.

Dr Ling, from the Australian Prostate Cancer Research Centre-Queensland and Institute for Biomedical Health & Innovation (IHBI) at QUT, said the results could be an important step towards fighting a disease that kills 3000 Australian men a year.

“The findings are quite significant,” Dr Ling said.

“What we wanted to demonstrate was whether that compound could stop the development of prostate tumours in the first place.

“In the past, other inhibitors tested in research trials have been shown to be up to 70 per cent effective, but we’re seeing 100 per cent of this tumour prevented from developing with PSP.

“Importantly, we did not see any side effects from the treatment.”

Dr Ling said conventional therapies were only effective in targeting certain cancer cells, not cancer stem cells, which initiated cancer and caused the disease to progress.

During the research trial, which was done in collaboration with The University of Hong Kong and Provital Pty Ltd, transgenic mice that developed prostate tumours were fed PSP for 20 weeks.

Dr Ling said no tumours were found in any of the mice fed PSP, whereas mice not given the treatment developed prostate tumours. He said the research suggested that PSP treatment could completely inhibit prostate tumour formation.

“Our findings support that PSP may be a potent preventative agent against prostate cancer, possibly through targeting of the prostate cancer stem cell population,” he said.

He said PSP had been previously shown to possess anti-cancer properties, and ‘turkey tail’ mushrooms (known as Coriolus versicolor or Yun-zhi) had been widely used in Asia for medicinal benefits.

However, Dr Ling said it was the first time it had been demonstrated that PSP had anti-cancer stem cell effects.

Although ‘turkey tail’ mushrooms had valuable health properties, Dr Ling said it would not be possible to get the same benefit his research showed from simply eating them.

A fundraiser has been organised in September to support further tests for the therapeutic potential of PSP against prostate tumours either alone or in combination with other anti-cancer compounds.

Source: (www.news.qut.edu.au)

The Electronic cigarette industry has been holding its breath for a while now. With legal action outstanding that could have banned the devices from the market, many suppliers have been waiting to increase technology investnment until the road forward for the industry was clear.

The road had been muddied by dis-information from parties worried by how this new industry and product was  going to severely impact their profits.

After a two year campaign by the FDA to intervene in the electronic cigarette industry and move the devices to regulation as ‘drug devices’ effectively getting them banned from the marketplace, it finally announced on Monday its decision to stop fighting repeated court decisions in favour of the industry and regulate the marketing of e-cigs under the Tobacco Control Act.

On its website Monday the FDA stated “The U.S. Court of Appeals for the D.C. Circuit, in Sottera, Inc. v. Food & Drug Administration, 627 F.3d 891 (D.C. Cir. 2010), recently issued a decision with regard to e-cigarettes and other products “made or derived from tobacco” and the jurisdictional line that should be drawn between “tobacco products” and “drugs,” “devices,” and combination products,  as those terms are defined in the FD&C Act.  The court held that e-cigarettes and other products made or derived from tobacco can be regulated as  “tobacco products” under the Act and are not drugs/devices unless they are marketed for therapeutic purposes. The government has decided not to seek further review of this decision, and FDA will comply with the jurisdictional lines established by Sottera.”

The decision should now open the market to ’serious’ suppliers and eliminate the fly by nights who offer teen enticing flavours and health claims in their marketing.

The decision was welcomed by inLife LLC, one of the first suppliers of electronic cigarettes to the US market and whose Regal 2 e-cig is seen as a market leader in the industry.

For more information about inLife:

UK : inLife UK

Spain (Español) (English)

Rest Of Europe: inLife Europe

inLife LLC, the Network Marketing business that introduced the electronic cigarette to the US market and is leading the way with cartridge technology manufactured in an FDA registered lab, is expanding through Europe after initially opening the business opportunity in the UK and then Spain.

Belgium followed and now inLife is looking for business leaders in Holland who can see the enormous market opening up in the electronic cigarette industry.

The electronic cigarette was once thought to be just a gimmick. That was until the tobacco industry and pharmecutical lobby stepped in to try and get them banned. They were first to realise that the e-cig posed a huge threat to their repspective industries as it provided a truly logical alternative to smoking tobacco allowing smokers to continue their habit without having to inhale the toxic chemicals that tobacco contains and for non smokers, without producing the harmful second hand smoke that has led to bans for tobacco smoking in public places.

There were concerns with a plethora of cheap chinese e-cigs flooding the market but as usual, the quality of such product has made them unviable. These leaves the market open to the quality brands such as inLife to make a huge dent in the $200 billion a year industry in the US and Europe alone.

Current Euro markets where leader are required are:

Austria            Germany        Netherlands      Spain                      Turkey
Denmark         Italy                 Romania             Sweden                  Ukraine
France            Ireland              Russia                 Switzerland          U. Kingdom

Interested parties should contact: Neil Ebsworth e-mail: neil@myinlife.co.uk